Engineered Extracellular Vesicles for BBB-Crossing IL-10 Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for intracerebral hemorrhage (ICH) lack effective methods to deliver therapeutic agents like IL-10 across the blood-brain barrier (BBB) to modulate microglia/macrophages, leading to non-specific targeting and reduced efficacy, while existing drug delivery methods face challenges in achieving consistent and satisfactory delivery to inflammatory sites.
Innovation Solution
Fusion of stem cell-derived extracellular vesicles (EVs) with liposomes, such as phosphatidylserine (PS) liposomes, to create chimeric EVs (cEVs) that carry therapeutic agents like IL-10, enhancing BBB penetration and targeted delivery to inflammatory sites, combined with imaging agents for real-time monitoring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional drug delivery methods are used to administer IL-10 systemically, then the therapeutic agent can reach the bloodstream, but the blood-brain barrier prevents adequate amounts from reaching the perihematomal regions
Solution Approach 1:
The patent uses stem cell-derived extracellular vesicles as intermediary carriers to transport IL-10 across the blood-brain barrier. These vesicles naturally traverse the BBB and deliver the therapeutic agent directly to the perihematomal regions, bypassing the barrier obstruction that prevents conventional systemic administration from achieving adequate drug levels.
Solution Approach 2:
The patent modifies the delivery parameters by changing from direct systemic administration to vesicle-mediated transport. This parameter change enables the therapeutic agent to cross the blood-brain barrier and achieve sufficient concentration in the target tissue, resolving the contradiction between bloodstream availability and brain penetration.
2Reliability
If IL-10 is directly administered systemically, then the drug can be delivered broadly, but it suffers from short half-life and leads to unwanted effects on other immune cells
Solution Approach 1:
The patent applies local quality by using extracellular vesicles to deliver IL-10 specifically to the perihematomal regions rather than distributing it systemically. This localized delivery approach concentrates the therapeutic effect at the target site while minimizing exposure and unwanted effects on other immune cells throughout the body.
Solution Approach 2:
The extracellular vesicles serve as a targeted delivery intermediary that directs IL-10 specifically to microglia and macrophages in the perihematomal regions. This intermediary system ensures the therapeutic agent reaches the intended target cells with high specificity, avoiding off-target effects on other immune cell populations.
3Reliability
If stem cell-based therapy is used to treat ICH, then regenerative potential is achieved, but biosafety concerns including infusional toxicity and tumorigenesis arise
Solution Approach 1:
The patent extracts the beneficial therapeutic components (immunomodulatory and regenerative factors) from living stem cells and encapsulates them within extracellular vesicles. This extraction approach retains the regenerative potential and therapeutic effects while eliminating the biosafety risks associated with live cell therapy, such as infusional toxicity and tumorigenesis.
Solution Approach 2:
The patent uses extracellular vesicles as disposable, acellular delivery vehicles that can be produced, characterized, and administered without the complexities of live cell therapy. These vesicles provide the therapeutic benefits of stem cell-derived factors without the long-term safety concerns of cell-based therapies.
4Reliability
If hMSC-EVs are used for immunomodulatory therapy, then anti-inflammatory effects are achieved, but rigorous quality control and technical optimization are lacking in current studies
Solution Approach 1:
The patent addresses quality control challenges by establishing defined parameters for vesicle characterization including size distribution, concentration, cargo content, and purity. By setting specific acceptance criteria for these parameters, the patent enables rigorous quality control that ensures consistent immunomodulatory efficacy while providing clear technical standards for optimization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cEVs effectively target microglia/macrophages, reducing hematoma volume and accelerating clearance, offering improved therapeutic and diagnostic efficacy with precise delivery and real-time monitoring.
Implementation Method 1
EVs, often also referred as exosomes in the literature, are small membranous blebs or vesicles released from almost all cell types, serving as mediators of intercellular communication to regulate a diverse range of biological processes
Implementation Method 2
a liposome including a therapeutic agent. In one aspect, the liposome includes at least one of phosphatidylcholine or phosphatidylserine
Implementation Method 3
Fusion of stem cell-derived extracellular vesicles (EVs) with liposomes, such as phosphatidylserine (PS) liposomes, to create chimeric EVs (cEVs) that carry therapeutic agents like IL-10
Implementation Method 4
combined with imaging agents for real-time monitoring
Data Source
AI summary
The present invention relates to a chimeric extracellular vesicle including a stem cell derived extracellular vesicle (SC-EV) and a liposome containing a therapeutic agent. The SC-EV, derived from stem cells, provides a carrier for the delivery of therapeutic agents. The liposome encapsulates a therapeutic agent, ensuring its stability and controlled release. The combination of SC-EV and liposome allows for targeted and efficient delivery of the therapeutic and imaging agents to specific cells or tissues, enhancing its therapeutic efficacy.